Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.53 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.50 |
| ▸ | HTR2A | P28223 | 1/20 | 0.50 |
| ▸ | HTR2C | P28335 | 1/20 | 0.50 |
| ▸ | HTR2B | P41595 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.49 |
| ▸ | GAA | P10253 | 3/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | MGAM | O43451 | 2/20 | 0.49 |
| ▸ | SI | P14410 | 2/20 | 0.49 |
| ▸ | MGAM2 | Q2M2H8 | 2/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | APAF1 | O14727 | 1/20 | 0.49 |
| ▸ | RECQL | P46063 | 1/20 | 0.49 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.48 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10968796 | 0.83 | PKM (0.55) | GPR84FFAR1HTR2AHTR2CHTR2B | |
| SCHEMBL10971099 | 0.82 | TACR1 (0.47) | GPR84FFAR1HTR2AHTR2CHTR2B | |
| SCHEMBL10890538 | 0.82 | MAPT (0.45) | GPR84FFAR1HTR2AHTR2CHTR2B | |
| Succinic Acid SCHEMBL31447438 | 0.82 | ADAM17 (0.54) | GPR84FFAR1HTR2AHTR2CHTR2B | |
| SCHEMBL6394945 | 0.81 | GPR84 (0.54) | GPR84FFAR1HTR2AHTR2CHTR2B | |
| SCHEMBL4666383 | 0.80 | GPR84 (0.60) | GPR84FFAR1HTR2AHTR2CHTR2B | |
| SCHEMBL3656418 | 0.78 | HTR2A (0.62) | GPR84FFAR1HTR2AHTR2CHTR2B | |
| SCHEMBL29611986 | 0.78 | HTR2A (0.62) | GPR84FFAR1HTR2AHTR2CHTR2B | |
| SCHEMBL6982959 | 0.78 | HTR2A (0.62) | GPR84FFAR1HTR2AHTR2CHTR2B | |
| SCHEMBL6986747 | 0.78 | HTR2A (0.62) | GPR84FFAR1HTR2AHTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 153 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12589171-B2 | 177-Lu labeled peptide for site-specific uPAR-targeting | TRT INNOVATIONS APS (DK) | 2026-03-31 | — | — | US | claimed |
| EP-4448020-B1 | UROKINASE-TYPE PLASMINOGEN ACTIVATOR RECEPTOR (UPAR)-PET/CT IN NEUROENDOCRINE NEOPLAMS | CURASIGHT AS (DK) | 2026-02-04 | — | — | EP | claimed |
| EP-4678194-A1 | THERAPEUTIC APPLICATION OF 64CU-LABELLED CONJUGATES FOR SITE-SPECIFIC UPAR-TARGETING | Curasight A/S (DK) | 2026-01-14 | — | — | EP | claimed |
| EP-4651912-A1 | RADIONUCLIDE LABELLED PEPTIDE CONJUGATE FOR SITE-SPECIFIC UPAR-TARGETING | Curasight A/S (DK) | 2025-11-26 | — | — | EP | claimed |
| US-20250319215-A1 | UROKINASE-TYPE PLASMINOGEN ACTIVATOR RECEPTOR (UPAR)-PET/CT IN HEAD AND NECK SQUAMOUS CELL CARCINOMAS (HNSCCS) | CURASIGHT AS (DK) | 2025-10-16 | — | — | US | claimed |
| US-12409240-B2 | Positron emitting radionuclide labeled peptides for human uPAR PET imaging | CURASIGHT A/S (DK) | 2025-09-09 | — | — | US | claimed |
| US-20250049971-A1 | UROKINASE-TYPE PLASMINOGEN ACTIVATOR RECEPTOR (UPAR)-PET/CT IN NEUROENDOCRINE NEOPLAMS | CURASIGHT A/S (DK) | 2025-02-13 | — | — | US | claimed |
| WO-2024153756-A1 | RADIONUCLIDE LABELLED PEPTIDE CONJUGATE FOR SITE-SPECIFIC UPAR-TARGETING | CURASIGHT A/S (DK) | 2024-07-25 | — | — | WO | claimed |
| EP-3590542-B1 | POSITRON EMITTING RADIONUCLIDE LABELED PEPTIDES FOR HUMAN UPAR PET IMAGING | CURASIGHT AS (DK) | 2024-01-03 | — | — | EP | claimed |
| EP-4197561-A1 | UROKINASE-TYPE PLASMINOGEN ACTIVATOR RECEPTOR (UPAR)-PET/CT IN NEUROENDOCRINE NEOPLAMS | Curasight A/S (DK) | 2023-06-21 | — | — | EP | claimed |
| US-20220202966-A1 | POSITRON EMITTING RADIONUCLIDE LABELED PEPTIDES FOR HUMAN UPAR PET IMAGING | CURASIGHT A/S (DK) | 2022-06-30 | — | — | US | claimed |
| US-11311637-B2 | Positron emitting radionuclide labeled peptides for human uPAR PET imaging | CURASIGHT A/S (DK) | 2022-04-26 | — | — | US | claimed |
| EP-1621546-B1 | Peptide ligands specific to immonoglobulins | TECNOGEN SPA (IT) | 2008-10-29 | — | — | EP | claimed |
| US-7026282-B1 | Peptide antagonists of the human urokinase receptor and method for selecting them | Cancerforskningsfonden AF 1989 (Fonden Til Fremme AF Exsperimentel Cancerforskning) (DK) | 2006-04-11 | — | — | US | claimed |
| EP-1621546-A1 | Peptide ligands specific to immonoglobulins | TECNOGEN S.C.P.A. (IT) | 2006-02-01 | — | — | EP | claimed |
| WO-2000001802-A2 | PEPTIDE ANTAGONISTS OF THE HUMAN UROKINASE RECEPTOR AND METHOD FOR SELECTING THEM | CANCERFORSKNINGSFONDEN AF 1989 (FONDEN TIL FREMME AF EKSPERIMENTEL CANCERFORSKNING) (DK) | 2000-01-13 | — | — | WO | claimed |
| US-12589171-B2 | 177-Lu labeled peptide for site-specific uPAR-targeting | TRT INNOVATIONS APS (DK) | 2026-03-31 | — | — | US | disclosed |
| US-20260069728-A1 | MULTI-TARGETING COMPOUND AND USE THEREOF | CHENGDU SHETAI MEDICAL TECHNOLOGY CO., LTD. (CN) | 2026-03-12 | — | — | US | disclosed |
| WO-1994003483-A1 | ENDOTHELIN RECEPTOR-BINDING COMPOUNDS | CHIRON CORPORATION (US) | 1994-02-17 | — | — | WO | disclosed |
| EP-0061768-B1 | N-AMIDO SUBSTITUTED DIPEPTIDES | USV PHARMACEUTICAL CORPORATION (US) | 1986-05-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12589171-B2 | 177-Lu labeled peptide for site-specific uPAR-targeting | LNPEP, XPNPEP2, PLAUR | GPR84 674/4885FFAR1 1754/4885HTR2A 120/4885 |
| US-20220202966-A1 | POSITRON EMITTING RADIONUCLIDE LABELED PEPTIDES FOR HUMAN UPAR PET IMAGING | PLAUR, PLAU, SERPINE1 | GPR84 384/4885FFAR1 488/4885HTR2A 3295/4885 |
| US-12409240-B2 | Positron emitting radionuclide labeled peptides for human uPAR PET imaging | PLAUR, PLAU, SERPINE1 | GPR84 384/4885FFAR1 488/4885HTR2A 3295/4885 |
| US-11311637-B2 | Positron emitting radionuclide labeled peptides for human uPAR PET imaging | PLAUR, PLAU, SERPINE1 | GPR84 384/4885FFAR1 488/4885HTR2A 3295/4885 |
| US-20250049971-A1 | UROKINASE-TYPE PLASMINOGEN ACTIVATOR RECEPTOR (UPAR)-PET/CT IN NEUROENDOCRINE NEOPLAMS | PLAUR, PLAU, PROKR1 | GPR84 231/4885FFAR1 601/4885HTR2A 1486/4885 |
| US-20260069728-A1 | MULTI-TARGETING COMPOUND AND USE THEREOF | CXCR4, CXCR2, GRPR | GPR84 62/4885FFAR1 60/4885HTR2A 1276/4885 |
| US-20250319215-A1 | UROKINASE-TYPE PLASMINOGEN ACTIVATOR RECEPTOR (UPAR)-PET/CT IN HEAD AND NECK SQUAMOUS CELL CARCINOMAS (HNSCCS) | PLAUR, PLAU, SERPINE1 | GPR84 636/4885FFAR1 217/4885HTR2A 2880/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.